The October issue of the journal
Experimental Neurology reports
on a study showing that MultiStem, a patented adult stem cell therapy
product from Cleveland-based biopharmaceutical firm
Athersys Inc., mitigated the damage of traumatic brain injuries in lab experiments.
MultiStem
uses multipotent adult progenitor cells, or MAPC, which "are obtained
from the bone marrow or other tissue sources of healthy, consenting
adult donors," according to an Athersys release. In an
abstract
of the study, the researchers explain, "Traumatic brain injury causes …
an increase in circulating immune cells leading to increased blood
brain barrier permeability. The intravenous injection of MAPC preserves
… the integrity of the blood brain barrier."
As an unrelated 2007
Science Daily article
explained, "The cells that make up the blood-brain barrier help the
brain and immune system communicate. … Changes to the blood-brain
barrier could give important clues about injuries to the central
nervous system and the growth of tumors."
MultiStem appears to be an unusually versatile therapy. The same week that the Experimental Neurology report was released,
Athersys presented findings from clinical trials with heart attack
patients at Transvascular Cardiovascular Therapeutics Conference in
Washington, D.C. That ongoing work involves
Dr. Marc Penn,
Director of Cardiovascular Cell Therapy at the Cleveland Clinic.
Athersys CEO Gil Van Bokkelen notes that while the recent trials were
designed primarily to test safety, "we also saw clear and compelling
signs that patients were experiencing improvement in heart function."
Van Bokkelen says Athersys and its many partners, including Pfizer, are
excited about the potential of MultiStem as a "very powerful
multifactor delivery system" that can treat a wide variety of patients.
Source: Athersys
Writer: Frank W. Lewis